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In schizophrenia, glutamic acid decarboxylase 1 (GAD1) disturbances are robust, consistently
observed, cell-type specific and represent a core feature of the disease. In addition,
neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing
interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizo-
phrenia, suggesting that dysfunction of the NPYþ cortical interneuronal sub-population
might be a core feature of this devastating disorder. However, modeling gene expression
disturbances in schizophrenia in a cell type-specific manner has been extremely challenging.
To more closely mimic these molecular and cellular human post-mortem findings, we
generated a transgenic mouse in which we downregulated GAD1 mRNA expression
specifically in NPYþ neurons. This novel, cell type-specific in vivo system for reducing gene
expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-
enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic
microRNA (miRNA) targeted to GAD1. The animals of isogenic strains are generated rapidly,
providing a new tool for better understanding the molecular disturbances in the GABAergic
system observed in complex neuropsychiatric disorders such as schizophrenia. In the future,
because of the small size of the silencing miRNAs combined with our BAC strategy, this
method may be modified to allow generation of mice with simultaneous silencing of multiple
genes in the same cells with a single construct, and production of splice-variant-specific
knockdown animals.
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Introduction
In the past decade, significant progress has been made
in describing detailed pathophysiologic features of
brain diseases, including signature patterns of altered
gene expression
1,2 and disruption of fundamental
neuroanatomical features of defined circuits.
3,4 Mecha-
nistic insight has been gained from the use of various
animal models, with the aim of mimicking alterations
of circuits, transmitter systems or cell subtypes that
may be involved in the behavioral disturbances
that characterize specific psychiatric and neurologic
diseases. Molecular perturbations of highly precise
specificity, however, have been difficult to achieve.
For example, complete deletion of a neurotransmitter
receptor from multiple cell types in a genetic model
may result in pathophysiological consequences, but
not necessarily related to a disease state. Moreover,
the traditional generation of mice by gene targeting
is time consuming and can be expensive. Thus,
the current state of transgenic models falls short
of modulating gene expression in disease-relevant
phenotypic and regional patterns.
5
At a molecular level, schizophrenia is characterized
by interrelated transcript deficits that consists of
downregulation of BDNF, TRKB, GAD67, SST, NPY,
PARV, CCK and GABRAD genes,
6–10 implicating the
cortical GABAergic interneuron as a central compo-
nent of the pathophysiology underlying the disease.
Perhaps the most widely replicated finding in post-
mortem studies of schizophrenia is a reduced expres-
sion of glutamic acid decarboxylase 1 (GAD1),
11–16
which is an enzyme responsible for the synthesis of
the inhibitory neurotransmitter GABA. Furthermore,
neuropeptide Y (NPY), which is a phenotypic marker
of a sub-population of GAD1-containing interneur-
ons,
17–20 shows reduced expression in the prefrontal
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www.nature.com/mpcortex in subjects with schizophrenia, suggesting that
dysfunction of NPYþ cortical interneurons is also an
additional core feature of this disorder.
9,20–23
To develop new strategies for more closely mimick-
ing these molecular and cellular human post-mortem
findings, we have established a novel, cell type-
specific in vivo system for regulation of gene expres-
sion; we combined a bacterial artificial chromosome
(BAC)
24,25 containing the NPY promoter-enhancer
elements, the reporter molecule (eGFP) and a
modified intron containing a synthetic microRNA
(miRNA)
26–28 targeted to glutamate decarboxylase 1
(GAD1) to generate a transgene that simultaneously
downregulates GAD1 mRNA expression and ex-
presses GFP, specifically in NPYþ neurons.
Materials and methods
BAC selection
BACs containing the mouse neuropeptide Y (mNpy)
locus (Chr6: 49700790-49860898, National Center for
Biotechnology Information (NCBI) Build 37.1) were
identified using the Human MapViewer resource
at NCBI (http://www.ncbi.nlm.nih.gov/projects/map
view/).
29 The mNpy gene itself is mapped at Chr6:
49772728-49779506bp, þ strand. The mNpy contain-
ing BAC RP24-386I9 was selected because the
chromosomal sequence was derived from a C57BL/6
genomic source and the mNpy gene was centrally
located within the BAC. The RP24-386I9 BAC was
provided by the BACPAC Resource at the Children’s
Hospital of Oakland Research Institute in Oakland,
California, (http://bacpac.chori.org/). The RP24-386I9
BAC was isolated from the original DH10B Escher-
ichia coli strain through standard alkaline lysis
protocol (available upon request) and transformed
into EL250 E. coli cells (kind gift of Dr Neil Copeland,
National Cancer Institute). The presence of the mNpy
locus in RP24-386I9 was verified using restriction
enzyme digest mapping.
miRNA selection and cloning
Two miRNAs targeting mGad1 were identified at the
RNAi Codex website (mp ID 283874: acgtggatcctgc
tgttgacagtgagcgaccacccagtctgacatcgatttagtgaagccacagatg
taaatcgatgtcagactgggtggctgcctactgcctcggaggatccacgt and
298398: acgtggatcctgctgttgacagtgagcgcgctctctactggtttgg
atattagtgaagccacagatgtaatatccaaaccagtagagagcttgcctactgc
ctcggaggatccacgt). Two partially overlapping oligos
were designed for each potential miRNA. PCR fill-in
of these oligos generated a 100-bp fragment that
contained an XhoI site at the 50 terminus and an
EcoRI site at the 30 terminus. This fragment was
ligated into the XhoI/EcoRI site of the TMP vector
(Open Biosystems, Huntsville, AL, USA) that con-
tains unique miR-30 sequences (9nt) at the 50 of the
XhoI site. PCR from this ligated plasmid amplified the
unique flanking miR-30 region and the intervening
GAD1 miRNA (B450bp total) while introducing
BamHI sites to the 50 and 30 regions of the PCR
product. The BamHI-digested fragment containing
fused miR30,miRNA:Gad1 was later inserted into a
b–globin minigene.
BAC targeting construct generation
BACs were targeted as described previously.
30 Two
partially overlapping oligos were generated that
contained two Lox 2272 recognition sites for CRE
recombinase, separated by a SpeI site and flanked by
NotI sites. This version of the recognition site for the
CRE recombinase was chosen to avoid interaction
with Lox sites that are commonly found in commer-
cially available BACs. These oligos were annealed
and filled in using Amplitaq Gold DNA polymerase,
digested with NotI and cloned into the pGEM 11ZF
(Promega Corporation, Madison, WI, USA). After
sequence verification, a minigene consisting of the 30
portion of exon 1, the entire intron 1 and the 50 portion
of exon 2 of the human b-globin gene was amplified
and cloned into the SpeI site of the Lox 2272
construct described above using XbaI sites engineered
into the 50 and 30 ends of the b-globin cassette. A BglII
restriction enzyme site was introduced (through PCR
mutagenesis) into intron 1 (57bp 30 to the exon 1
splice donor site) of the b-globin minigene to permit
introduction of the miR30, miRNA:Gad1 fragment.
Digestion of this plasmid with NotI released a 764-bp
fragment, which was subsequently cloned into the
NotI site of pEGFP-N1-BglII/NcoI (see below).
The BglII restriction site was added to pEGFP-N1
(Clontech Laboratories, Inc, Mountain View, CA,
USA) by inserting an oligo at the AflII site, which
was located at the 30 end of the SV40 polyadenilation
signal. This generated a plasmid designated as
pEGFP-NI-BglII. The NotI fragment containing Lox
2272 flanked b-globin minigene with miR30, miRNA:
Gad1 was inserted into the NotI site of pEGFP-NI-
BglII, which was located immediately after the eGFP
coding sequences. Two separate versions of this
construct, one for each miRNA:Gad1 (283874 and
298398) were generated. These constructs were
denoted Intermediate constructs. As in these con-
structs the expression of eGFP and the b-globin
minigene was driven by the cytomegalovirus (CMV)
promoter (inherent to the eGFP-N1 parent vector) and
not the restricted NPY promoter, they were suitable
for testing the silencing effect of the miRNA:Gad1
precursor in cell culture assays.
A 500-nt fragment symmetrically spanning the
translation start site (ATG codon) of the Npy gene
was generated using PCR. During the amplification,
an NcoI restriction enzyme site (CCATGG) was
inserted by mutation of the nucleotides surrounding
the ATG codon. The fragment was then cloned in
pSTBlue-1 (Novagen, Madison, WI, USA), which is a
TA cloning vector system that contains EcoRI restric-
tion enzyme sites flanking the TA cloning insertion
site. The NcoI site became a recipient of an NcoI
fragment containing eGFP and the floxed minigene
from the intermediate construct described above. In
this way, eGFP and the floxed minigene were
surrounded by the Npy homology arms necessary for
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neomycin resistance cassette (gift of Neil Copeland,
National Cancer Institute and National Institute of
Mental Health) was cloned into the BglII site and with
this the targeting construct was completed. An EcoRI
targeting fragment was then released from it and used
for homologous recombination with the Npy contain-
ing BAC RP24-386I9 as described.
31 BACs were then
screened by PCR and confirmed with restriction
mapping and sequence analysis for correct modifica-
tions. The E. coli strain containing the modified BAC
was then induced with arabinose for the expression of
FLP recombinase, which removed the FRT-flanked
neomycin resistance cassette. Proper recombination
was confirmed with restriction mapping and se-
quence analysis of the region of interest.
Mouse generation
The BAC DNA construct was isolated with alkaline
lysis and purified with Sepharose CL-4B chromato-
graphy as described previously.
32 Transgenic mice
were generated by injection of circular BAC
DNA construct into fertilized mouse oocytes by
the Vanderbilt Transgenic Mouse/Embryonic Stem
Cell Shared resource (http://www.vcscb.org/shared_
resource/). Transgenic founder mice were identified
by PCR using construct-specific primer pairs.
Cell culture/western blotting
Intermediate construct DNA (CMV-eGFP, miRNA:Gad1)
was co-transfected into HEK-293 cells (American
Type Culture Collection) along with a GAD1 expres-
sion construct (IMAGE clone 5358787) in a 3:1 ratio
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Cells were incubated for either 24 or 48h after
transfection, at which point they were harvested into
500ml RIPA buffer (150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate
and 50mM Tris pH 8.0) containing protease inhibi-
tors. Western blot was performed using 50mg total
protein per lane with 1:5000 dilution of mouse anti-
Gad1 monoclonal antibody (Millipore, Billerica, MA,
USA) and 1:5000 dilution of anti-mouse-horseradish
peroxidase (Jackson Immunoresearch, West Grove,
PA, USA). Glyceraldehyde-3-phosphate dehydrogen-
ase protein levels served as a reference using a rabbit
antibody (Abcam, Cambridge, MA, USA) and anti-
rabbit-horseradish peroxidase. GFP expression was
confirmed by fluorescence imaging of transfected
cells using an Axiovert 40 CFL inverted microscope
(Carl Zeiss Microimaging, Inc, Thomwood, NY, USA)
fitted with a digital camera.
Immunohistochemistry
For immunolocation studies, animals were deeply
anesthetized with isoflurane and transcardially per-
fused with 1  phosphate buffer (PB) solution for
1min, followed by 4% paraformaldehyde made up in
0.1M PB (pH 7.4) for 11–30min at room temperature.
All procedures were performed in accordance with
the guidelines of the American Association for
Laboratory Animal Science and the Vanderbilt Uni-
versity Institutional Animal Care and Use Committee
Protection of Research Subjects. Brains were then
removed and postfixed for 4h at room temperature in
4% paraformaldehyde. After washing extensively
with PB, the tissue was equilibrated in 30% su-
crose–phosphate buffer and subsequently transferred
to a plastic mold filled with Tissue-Tek optimal
cutting compound (Sakura Finetek, Torrance, CA,
USA), frozen on dry ice and stored at  701C until
sectioned. Coronal sections, 50-mm thick, were pre-
pared with a cryostat (CM1950, Leica Microsystems,
Bannockburn, IL, USA), and then washed several
times in 0.1M PB. Sections were stored at  201Ci n
an antifreeze solution until immunostaing.
Brain sections were extensively washed in PB and
then incubated for 1h in 10% normal donkey serum
in 0.1mM PB (pH 7.4). Immunostaining for eGFP was
performed either with a rabbit anti-GFP (Invitrogen;
1:2000) or chicken anti-GFP (Abcam; 1:2000). Im-
munostaining for NPY was performed using 1:1000
dilution of rabbit anti-NPY antibody (Peninsula
Laboratories, San Carlos, CA, USA). Additional rabbit
anti-NPY antibodies (Immunostar, Inc, Hudson, WI,
USA; 1:1000) and sheep anti-NPY (Millipore; 1:1000)
were used to confirm NPY-GFP co-expression pattern
(data not shown). For GAD1 immunostaining, sec-
tions were pre-incubated with 70mgml
–1 of a mono-
valent Fab’ fragment of donkey anti-mouse immuno-
globulin G (Jackson Immunoresearch, West Grove, PA,
USA) to block endogenous mouse immunoglobulins,
and proceeded with the standard protocol for im-
munolabeling with mouse anti-GAD-1 (Millipore;
1:2000). The following secondary antibodies (Jackson
Immunoresearch) were used for fluorescence detec-
tion: donkey anti-rabbit DyLight488, donkey anti-
rabbit Cy3, donkey anti-chicken DyLight488, donkey
anti-sheep Cy3 and donkey anti-mouse Cy3 (all
diluted 1:250). All sections were incubated with
primary antibodies for 72h at 41C, washed exten-
sively and incubated in secondary antibodies for
3h at room temperature. Immunolabeled sections
were mounted in Fluoromont-G (Southern Biotech,
Birmingham, AL, USA) and examined using a
fluorescence microscope (Leica Microsystems, Inc,
Bannockburn, IL, USA). For the direct detection of
eGFP fluorescence, cryostat sections were washed
three times in 0.1M PB, and then mounted on slides.
Images were stored and analyzed using IPLAb for
Windows (version 4.03; BD Biosciences, San Jose, CA,
USA) scientific imaging software. Brightness and
contrast were adjusted for the whole image using
Adobe Photoshop CS3 software (Adobe Systems, Inc,
San Jose, CA, USA).
Results
The construct
The construction of a hybrid reporter/miRNA knock-
down transgenic construct was achieved through
Generation of BAC-miRNA transgenic mice
KA Garbett et al
989
Molecular Psychiatrya multi-step cloning procedure, which is depicted
in Supplementary Material 1. The final construct
(Figure 1a) has several parts as follows. (1) A centrally
located minigene containing part of the first exon,
intervening intron and second exon of the human
b-globin gene, providing the necessary sequence elements
for expression modulation. This non-coding sequence
exerts an effect as a ‘carrier’ for a synthetic miRNA
directed against the GAD1 mRNA. The realization
that intronic localization of a miRNA (as is observed
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protein-coding capability of the gene empirically
shows that intron splicing proceeds miRNA excision;
thus, we located the miRNAwithin an intron to allow
excision of the miRNA by class 2 RNase III enzyme,
DROSHA, without destruction of the coding potential
of the remaining transcript.
33 The processed miRNA
binds the GAD1 mRNA, and the resulting miRNA:mRNA
complex is targeted to the RNA-induced silencing
complex for degradation.
26 The minigene sequence is
flanked by LoxP sites, which will allow excision of
the gene-silencing aspect of the transgene in vivo
while retaining the potential to express eGFP. This
could theoretically be used to assess whether pheno-
types associated with the transgene are due to
gene expression silencing or insertional inactivation
of a non-related gene during transgene integration.
(2) 50 to the silencing minigene an eGFP sequence
was inserted in frame with the start codon of the
BAC-encoded NPY gene (expression of NPY itself
from the transgene was thereby eliminated), resulting
in expression of eGFP in cells in which the transgene
is expressed. (3) 30 to the silencing minigene is a
strong polyadenylation sequence (SV40-pA) to ensure
that the transgene does not ‘read through’ to down-
stream NPY coding regions. (4) Finally, the eGFP-
silencing minigene-SV40-pA sequences are flanked
by the NPY BAC, containing the full complement of
NPY genetic regulatory elements, thus providing cell
type-specific expression.
The specific miRNA for the gene of interest (GAD1)
was inserted into the intron 50 proximal to the branch
point required for lariat formation during pre-mRNA
processing. The human b-globin gene has been
extensively characterized in studies of mRNA proces-
sing,
34 including the structure of the intron; insertion
of sequence >20bp 50 of the branch point does not
interfere with RNA processing. The presence of our
Figure 1 Generation and validation of the Tg(Npy-eGFP/miRNA:Gad1)1KM mice. (a) Schematic linear representation of the
construct. Flanking regions of the construct are derived from the driver NPY BAC that provides interneuron subtype-specific
expression of the construct. The 50 region of the driver BAC (NPY promoter region) ensures specific expression of eGFP, and
the SV40-pA ensures proper polyadenylation. The construct, containing a non-functional (not translated) part of b-globin
exons 1 and 2, and intron 1 in its entirety, is spliced by the cellular machinery, liberating the intron that contains the 70–100
nucleotide long double-stranded miRNA directed against GAD1. The spliced intron-miRNA:Gad1 is processed through
DROSHA and exported from the nucleus. In the cytoplasm the miRNA binds to and degrades the endogenous GAD1 mRNA
through an RNA-induced silencing complex (RISC).
33,50 The eGFP mRNA is translated, thus fluorescently labeling cells of
interest. The presence of LoxP sites facilitates generation of animals lacking the silencing part of the miRNA:Gad1 construct,
but still expresses eGFP, to serve as controls. (b) miRNA-mediated downregulation of GAD1 in vitro. CHO cells co-transfected
with GFP reporter vector alone ( ), two different intermediate constructs (GFP reporter vectors containing two different
synthetic miRNAs directed against GAD1—nos. 1 and 2), and GAD1 expression vector. The cells were harvested at 24 and
48h after transfection. Western blot analysis confirmed that the two different miRNAs against GAD1 were correctly
processed from the b-globin intron and that both miRNAs strongly downregulated GAD1 expression. Similar results have
been obtained in HEK293 cells with stable expression of GAD1 that were engineered in our laboratory (data not shown). The
same cells transfected with CMV-eGFP,miRNA:Gad1 show high levels of eGFP expression, confirming that the construct
performs as expected. In addition, the processing of the miRNA from the b-globin intron in the construct does not interfere
with eGFP protein translation. (c) Identification of founder animals by PCR-based genotyping of founder animals using eGFP
primers with genomic DNA as template. The first lane represents size marker, and the last lane corresponds to positive
control, with the remaining lanes containing eGFP amplification products from the genomic DNA of individual animals. The
550-nt product on a 1% agarose gel indicates construct incorporation into the genome of four founder animals (NPY 1, 3, 4
and 5). Similar results were obtained by Southern hybridization (data not sown). (d) Quantitative PCR (qPCR) amplification
plot from frontal cortex of founder animals using eGFP construct-specific primers. The y axis denotes PCR product
accumulation, and the x axis denotes amplification cycle number. Note that two (NPY1 and NPY4) of the four founder lines
that incorporated the NPY-BAC/GAD1-miRNA construct reported functional eGFP expression. These lines were used for
further characterization. (e) The NPY-BAC/GAD1-miRNA construct showed the expected tissue distribution in the brain.
Micrographs depict the fidelity of co-localized eGFP and NPY in adult transgenic animals from line Tg(Npy-eGFP/
miRNA:Gad1)1KM. The left column micrographs denote eGFP immunostaining, middle column micrographs represent
sections labeled with anti-NPY and the right column micrographs illustrate pseudocolored composite of eGFP-NPY co-
localization in the same tissue sections. In the cortex, roman numerals denote cortical laminae. Hippocampus abbreviations:
gcl, granule cell layer; h, hilus; ml, molecular layer. Note that all GFPþ neurons are also NPYþ, and all NPYþ cells are
GFPþ, suggesting that the construct is specifically and exclusively expressed in the phenotypically appropriate target cell
population. Calibration bar=100mm. (f, g) Tg(Npy-eGFP/ miRNA:Gad1)1KM animals show undetectable GAD1 levels in the
frontal cortex and hippocampus of NPYþ cells compared with NPYþ neurons in control animals. eGFP-GAD1 double-
immunohistochemistry (eGFP, green; GAD1, red) was performed from a coronal section through the frontal cortex and
hippocampus of a transgenic animal. Wild-type control littermate was double stained against NPYand GAD1. Same cells are
denoted by arrowheads. In the cortex, roman numerals denote cortical laminae. Hippocampal abbreviations: f, hippocampal
fissure; gcl, ganglion cell layer; h, hilus; ml, molecular layer; slm, stratum lacunosum moleculare; sp, stratum pyramidale;
sr, stratum radiatum. Note that all NPYþ cells (white arrows) are GAD1þ in control animals, whereas none of the eGFPþ
(and thus NPYþ) neurons (white arrows) show GAD1 staining in the transgenic mice. Moreover, note the large number
of single-labeled GAD1þ neurons that are eGFP– in the transgenic line. These data indicate selective, miRNA-mediated,
cell type-specific downregulation of GAD1 in NPYþ interneurons. Calibration bars=60mm (overview figures) and 100mm.
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to the eGFP coding region, did not impair eGFP
protein expression and resulted in the generation of a
miRNA competent to target RNA-degradation com-
plexes to the GAD1 mRNA (see below).
In vitro silencing of GAD1
To analyze the validity of our approach, we tested an
intermediate eGFP-miRNA construct (before integra-
tion into the NPY BAC) on CHO and HEK293 cell
systems. Both transiently transfected CHO cells with
GAD1 and HEK293 cells with stable incorporation of
GAD1 were co-transfected with our miRNA silencing
construct (under the control of the CMV promoter).
Two different silencing constructs were tested, each
harboring a different miRNA directed against GAD1.
Transfection with either GAD1 miRNA construct
(eGFP/miRNA:Gad1) resulted in a >90% reduction
in GAD1 protein at 24 and 48h after transfection
(Figure 1b) in both cell lines. Furthermore, the
transfected cells expressed high levels of eGFP,
confirming that the eGFP coding potential of the
construct was maintained with the addition of the
minigene and that excision of the miRNA did not
interfere with the translation of eGFP (as predicted).
Generation of NPY BAC-driven GAD1 miRNA-silenced
transgenic animals
To accurately direct expression of the GAD1-targeted
miRNA to an interneuronal sub-population of interest
(NPY-expressing cells), we included the enhancer
regions that specify expression of the desired driver
gene (NPY). This interneuron subtype comprises
approximately 8% of the total neocortical GABAergic
interneuron population in mice,
35 providing a strin-
gent test of specificity of the BAC-driven silencing
strategy. The driver gene is relatively small, facilitat-
ing identification of a BAC that contained a centrally
located coding region. This feature greatly improved
the likelihood of including all of the necessary
regulatory regions. We identified BACs using the
NCBI genome browser (Build 36), restricting the
selection to BACs containing C57BL/6 genomic DNA
(RP23/RP24, bacpac.chori.org) to allow generation of
C57BL/6 congenic animals. Although BAC clones are
‘tiled’ to the genomic sequence by sequencing their
ends and identifying the appropriate region of the
genome, errors can occur through the curation
process or during transfer to the ‘recombineering’
bacteria. To confirm the correct, linearly intact
arrangement of the genomic DNA in the BACs,
restriction mapping was performed using the restric-
tion enzyme SpeI after transformation into the EL250
‘recombineering’ E. coli strain.
31 Digests were sepa-
rated by field inversion gel electrophoresis and band
sizes approximated by comparison with a 5-kb
molecular weight ladder. All band sizes were as
predicted based on NCBI sequence data, confirming
the identity and structure of the sequence contained
in the BAC after transfer to EL250 cells.
Supercoiled recombinant BAC DNAwas injected at
approximately 1ngml
–1 into C57BL/6 embryos by the
Vanderbilt Transgenic Mouse/Embryonic Stem Cell
Shared Resource. C57BL/6 embryos (rather than
C57BL/6 DBA F1 embryos) were used, which
resulted in founder transgenic animals that were
congenic C57BL/6 at their inception. This strategy
eliminates the confound of cross-strain allelic varia-
tion and the need for time-consuming backcrossing
before downstream analyses. Founder animals were
identified by PCR genotyping using GFP-specific
primers. Four founders (Figure 1c) were mated to
C57BL/6 animals and transgenic lines were estab-
lished. GFP expression was detected in the forebrain
of two out of four transgenic lines (Figure 1d). Line
NPY1 (Tg(Npy-eGFP/miRNA:Gad1)1KM ) was chosen
for further characterization, as in the other eGFP-
expressing transgenic mouse line (NPY4—Tg(Npy-
eGFP/miRNA:Gad1)4KM), as well as several wild-
type and transgenic animals from the same mother-
developed hydrocephalus. The NPY BAC/GAD1
miRNA transgenic animals from line NPY4 showed
identical eGFP expression patterns as the transgenic
animals from the NPY1 line. The Tg(Npy-eGFP/
miRNA:Gad1)1KM animals expressed consistent and
high levels of the minigene carrying the GAD1
microRNA in the frontal cortex (Supplementary
Material 2).
Anatomical characterization of NPY BAC/GAD1
miRNA transgenic animals
Normal distribution of the NPY mRNA and protein
has been extensively studied in the rodent brain. NPY
is expressed at high levels in a small sub-population of
hippocampal
18,36 and neocortical interneurons,
17,37–39
and in the arcuate nucleus of the hypothalamus.
40,41
In brain sections from transgenic animals, strong
eGFP fluorescence was detected without immunos-
taining, although visualization of dendritic arbors
markedly improved when the eGFP signal was
amplified by immunohistochemical methods (Supple-
mentary Material 3). In a regional survey of the
brains derived from Tg(Npy-eGFP/miRNA:Gad1)1KM
transgenic animals, we found that eGFP expression
correlated with previous descriptions of NPY dis-
tribution in wild-type rodents (Figure 1e, left col-
umn).
19,35,39,42–44 Coexpression of eGFP with
endogenous NPY was also confirmed in double-
labeling studies, which showed a >99% co-localiza-
tion between NPY immunoreactivity and transgenic
eGFP expression (Figure 1e, right column). The vast
majority of the neocortical interneurons showed
morphology of neurogliaform cells. In addition,
numerous Martinotti-like cells (Supplementary
Materials 4 and 5)
19,43 and occasional double-bouquet
interneurons were detected. In the hippocampus, the
appearance and localization of cells corresponded to
neurogliaform
44 and Ivy-type interneurons,
42 which
are known to express NPY. Overall, the morphology
and distribution of the labeled interneurons across
the different brain structures suggested that the
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populations that normally express the NPY gene.
After the successful expression of the transgene in a
native NPY pattern, we next evaluated the efficacy of
the GAD1-directed miRNA in reducing GAD1 expres-
sion in the targeted interneurons. Because NPYþ
cells make up such a small proportion of total
GAD1þ cells in any brain area, tissue measurement
of transcript or protein would not be sufficiently
sensitive to reveal differences between control and
transgenic animals. We thus performed GFP-GAD1
double-fluorescence immunohistochemistry to char-
acterize effective knockdown of protein expression
(through gene transcript degradation) in NPYþ cells.
There was intense GAD1 immunoreactivity in single-
labeled interneurons throughout the cerebral cortex,
but in the same sections, virtually none of the GFP-
positive (for example, NPYþ) cells showed detect-
able GAD1 expression in the frontal cortex and
hippocampus (Figures 1f and g). The absence of
GAD1 immunoreactivity was evident in all NPY cell
types examined, and there did not seem to be a
selective cell loss due to the absence of GAD1
expression in these targeted cells. The cellular
selectivity of the knockdown was striking, consistent
with successful cell type-specific targeting of reduced
GAD1 expression to undetectable levels.
Discussion
In this study we report the development of a new
strategy to modulate gene expression in a phenotypic
and regional manner, facilitating wide dissemination
of a straightforward genetic approach for investigators
to establish in vivo disease models based on available
pathophysiological data for disease states.
5 In schizo-
phrenia, GAD1 disturbances are robust, replicable
and represent a core feature of the disease,
14,15 making
it a leading candidate for developing transgenic
animal models that more closely mimic the disease
phenotype. However, GAD1 downregulation in schi-
zophrenia is not uniform across all the interneuronal
sub-populations: neurons containing parvalbumin
(PARV), somatostatin (SST) and NPY seem to be
preferentially affected in a complex pattern.
9 Impor-
tantly, NPYþ interneurons in the cortex tend to
provide inhibitory inputs to the distal dendrites of
pyramidal neurons
14,19 decreasing excitability in
cortical circuits. As a result, these neurons seem to
be critical for learning and memory.
45 Furthermore, as
NPYþ cells are affected by the disease process of
schizophrenia,
9,20–23 the success in this study in
selectively reducing GAD1 expression in these cells
provides a unique opportunity to define the role of
these cells in cortical pathophysiology that may relate
to the disease.
The novel strategy for rapidly generating transgenic
mouse lines uses NPY BAC-mediated expression of a
synthetic GAD1 miRNA precursor to direct the cell
type-specific downregulation of a defined transcript
through an endogenous miRNA processing cellular
mechanism. Furthermore, due to incorporation of an
eGFP coding sequence, the targeted cells are identifi-
able in both live and fixed tissues. In addition, the
components of our targeting construct are modular,
which will allow investigators to perform a relatively
easy exchange of the miRNA precursor or the
sequences homologous to the driver gene.
The advantages of this in vivo gene silencing system
are numerous. First, we achieve cell type-specific
downregulation of transcripts (in which this specifi-
city depends on the driver gene present on a BAC)
and visualize the targeted cells by expressing a
reporter gene eGFP. This native fluorescence will
facilitate further characterization of the targeted cells
with a variety of analytical techniques, including (but
not limited to) electrophysiology, morphological
analyses, laser dissection microscopy for genomic
analysis, double-labeling studies and flow sorting.
Second, these transgenic mice are congenic on the
C57BL/6 background, and can be generated rapidly
(several months) and at a low cost. This allows
production of a variety of genetically manipulated
animals. Third, to achieve complex gene modulation
that more accurately mimics brain disease pathophy-
siology, the miRNA BAC mice can be crossed with
other mouse models, including multiple transgenic
lines and various knockout animals. Finally, because
of the small size of the silencing miRNAs, this
method may allow targeting of specific splice var-
iants, generating splice-variant-specific knockdown
animals. We are currently establishing this technol-
ogy for dissemination.
The in vivo miRNA silencing technology can be
further developed in at least three additional direc-
tions to study cell-specific silencing of gene expres-
sion. First, the construct produced in this study can
be placed under the control of an inducible promoter
(for example, tetracycline-dependent activators and
repressors),
46,47 which would allow the study of
the developmental effects of gene silencing in
the targeted, GFP-expressing cells (Supplementary
Material 6A). Second, the eGFP gene sequence can
be exchanged for any Red Fluorescent Protein
sequence
48,49 (Supplementary Material 6B), allowing
combinatorial breeding of various miRNA-silenced
mice, in which the multiple silenced sub-populations
of live neurons would be readily identifiable by the
use of different fluorescent proteins. Finally, the
construct could be further modified to include multi-
ple introns, each harboring miRNAs against different
gene products, enabling simultaneous silencing of
multiple genes in the same cells with a single
construct (Supplementary Material 6c). The metho-
dological advances reported in this study provide
opportunities to generate a complex pathophysiology
in mice that reflects more accurately unique features
of different brain diseases.
In the context of research related to gaining
mechanistic insight of the core biological distur-
bances in schizophrenia, our characterization of the
Tg(Npy-eGFP/miRNA:Gad1)1KM animals will allow
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siological and behavioral consequences of the GAD1
deficit in the NPY-expressing cells. Furthermore, a
combined analysis of the NPY-, PV-, CCK- and SST-
BAC-driven GAD1 miRNA-silenced mice (which are
currently in production in our laboratory) will greatly
contribute to an understanding of the specific role
that different interneuronal sub-populations have in
cortical inhibition, working memory and cognition.
In turn, this will shed light on the mechanisms that
cell type-specific GABAergic disturbances have in
phenotypic manifestations of schizophrenia.
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